OraSure Technologies (EP3) Stock Overview

Develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. More details

EP3 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 5.42% per year

Risk Analysis

Shares are highly illiquid

EP3 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

OraSure Technologies, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for OraSure Technologies
Historical stock prices
Current Share Price	US$3.31
52 Week High	US$0
52 Week Low	US$0
Beta	1.01
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	EP3	CH Medical Equipment	CH Market
7D	0%	-2.6%	2.6%
1Y	n/a	-19.2%	11.8%

Return vs Industry: Insufficient data to determine how EP3 performed against the Swiss Medical Equipment industry.

Return vs Market: Insufficient data to determine how EP3 performed against the Swiss Market.

Price Volatility

Is EP3's price volatile compared to industry and market?
EP3 volatility
EP3 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	4.3%
Market Average Movement	4.4%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	2.4%

Stable Share Price: EP3's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine EP3's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1987	500	Carrie Eglinton Manner	www.orasure.com

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device.

OraSure Technologies, Inc. Fundamentals Summary

How do OraSure Technologies's earnings and revenue compare to its market cap?
EP3 fundamental statistics
Market cap	CHF 235.94m
Earnings (TTM)	-CHF 59.55m
Revenue (TTM)	CHF 89.65m

2.6x

P/S Ratio

-4.0x

P/E Ratio

Is EP3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EP3 income statement (TTM)
Revenue	US$113.02m
Cost of Revenue	US$65.25m
Gross Profit	US$47.77m
Other Expenses	US$122.84m
Earnings	-US$75.07m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.09
Gross Margin	42.27%
Net Profit Margin	-66.42%
Debt/Equity Ratio	0%

How did EP3 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/16 04:58
End of Day Share Price	2026/06/08 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OraSure Technologies, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Charley Jones	Barrington Research Associates, Inc.
Karen Koski	BTIG
Mark Massaro	Canaccord Genuity